Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28876911 | 0.94 | PPARG (0.51) | NPC1RAB9APPARGPPARAALDH1A1 | |
| SCHEMBL3796731 | 0.88 | ALDH1A1 (0.49) | NPC1RAB9APPARGPPARAALDH1A1 | |
| SCHEMBL3344661 | 0.87 | EPHX2 (0.47) | NPC1PPARGPPARAALDH1A1 | |
| SCHEMBL11242757 | 0.86 | KMT2A (0.58) | NPC1RAB9APPARGPPARAALDH1A1 | |
| SCHEMBL8076310 | 0.85 | PNMT (0.48) | SMN1; SMN2PNMTIDO1SLC6A2SLC6A4 | |
| SCHEMBL21400206 | 0.85 | NPC1 (0.46) | NPC1RAB9APPARGPPARAALDH1A1 | |
| SCHEMBL11567124 | 0.85 | NPC1 (0.46) | NPC1RAB9APPARGPPARAALDH1A1 | |
| SCHEMBL13235838 | 0.85 | NPC1 (0.46) | NPC1RAB9APPARGPPARAALDH1A1 | |
| SCHEMBL14271140 | 0.83 | SLC6A2 (0.47) | NPC1RAB9APPARGPPARAALDH1A1 | |
| SCHEMBL9767979 | 0.82 | ALDH1A1 (0.52) | NPC1RAB9APPARGPPARAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3564216-B1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2021-10-27 | — | — | EP | disclosed |
| EP-3564216-B1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2021-10-27 | — | — | EP | disclosed |
| US-11034659-B2 | Pyrimidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-15 | — | — | US | disclosed |
| US-11034659-B2 | Pyrimidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-15 | — | — | US | disclosed |
| US-20200172494-A1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-06-04 | — | — | US | disclosed |
| US-20200172494-A1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-06-04 | — | — | US | disclosed |
| EP-3564216-A1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-11-06 | — | — | EP | disclosed |
| EP-3564216-A1 | PYRIMIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034659-B2 | Pyrimidine derivative | GPR39, CFTR, TMEM109 | NPC1 787/4885RAB9A 1147/4885PPARG 566/4885 |
| US-20200172494-A1 | PYRIMIDINE DERIVATIVE | GPR39, CFTR, TMEM109 | NPC1 787/4885RAB9A 1147/4885PPARG 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.